Watch Live

Tweet TWEET

Biota Announces Approval of Definitive Merger Agreement by Nabi

Biota Announces Approval of Definitive Merger Agreement by Nabi
Shareholders 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 10/23/12 --  Biota Holdings
Limited (ASX: BTA) (Biota) announces that the shareholders of Nabi
Biopharmaceuticals Inc. (Nabi) have approved proposals related to the
business combination transaction with Biota, at a shareholders
meeting held at 4:30pm EDT on October 22, 2012 in Bethesda, MD.  
As set out in the Explanatory Memorandum on August 6, 2012, Nabi
shareholders were to vote on a number of proposals, including the
following: 


 
--  To increase the authorised shares in Nabi to 200,000,000;
--  To approve the issuance of shares of Nabi to Biota shareholders as
    contemplated by the Merger Implementation Agreement;
--  To approve, at Nabi directors' sole discretion, a share consolidation
    in the range of four-to-one to eight-to-one; and
--  To approve the change of name from Nabi Biopharmaceuticals to Biota
    Pharmaceuticals Inc.

  
Each of these proposals was approved by the requisite majority votes. 
Biota shareholders will meet at 2:00pm on October 23, 2012 in
Melbourne, Australia to approve the Revised Scheme of Arrangement in
relation to the transaction. Shareholders unable to attend the
meeting will be provided with results immediately upon conclusion. 
About Biota 
Biota is a leading anti-infective drug development company based in
Melbourne Australia, with key expertise in respiratory diseases,
particularly influenza. Biota developed the first-in-class
neuraminidase inhibitor, zanamivir, subsequently marketed by
GlaxoSmithKline as Relenza. Biota research breakthroughs include a
series of candidate drugs aimed at treatment of respiratory syncytial
virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has
a well advanced program for human rhinovirus (HRV) infection with a
completed Phase IIb study in asthmatic subjects. 
In addition, Biota and Daiichi Sankyo co-own a range of second
generation influenza antivirals, of which the lead product lnavir(R),
is marketed in Japan. Biota holds a contract from the US Office of
Biomedical Advanced Research and Development Authority (BARDA) for
the advanced development of laninamivir in the USA.  
Relenza(TM) is a registered trademark of the GlaxoSmithKline group of
companies. 
 Inavir(R) is registered to Daiichi Sankyo. 
Further information
Investor/Analyst Enquiries
Biota Holdings Limited 
Peter Cook 
T: +61 3 9915 3720
Damian Lismore 
T: +61 3 9915 3721 
Shareholder Enquiries
Biota Shareholder Information Line
T: 1300 306 230 (within Australia)
T: +61 2 8280 7169 (International)
Between 8:30am and 7:30pm 
(Melbourne time) 
Media Enquiries
Nerida Mossop
Hinton & Associates
T: +61 3 9600 1979
M: +61 437 361 433 
Felicity Williams
Hinton & Associates
T: +61 3 9600 1979
M: +61 416 770 012 
US Enquiries
Hershel Berry
Blueprint Life Science Group
M: +1 415.375.3340 Ext. 102